Healthline reports that federal regulators have agreed to review applications for potentially less expensive generic versions of the tirzepatide medications Mounjaro and Zepbound. In the article, AACE President Dace L. Trence, MD, MACE, emphasized that cost remains a major barrier to starting and continuing these medications, and noted their potential benefits for blood pressure, cholesterol, and cardiovascular risk.